ARTICLE | Clinical News
Oxytocin: Interim Phase IIa data
May 31, 2010 7:00 AM UTC
Interim data from 25 evaluable patients in a double-blind Phase IIa trial showed that 47% of intranasal oxytocin patients reported at least a 50% reduction in pain scores vs. 11% for placebo. The tria...